Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
martes, octubre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Johnson & Johnson
JNJ
NYSE
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$255.50
Últ. Act.: Oct 20, 4:23 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Dividendos
Comparar
Opciones
Informe de acciones
Privacy Manager
Ganancias:
Los beneficios de Q3 2026 se publicaron el mar oct 13th, antes de la apertura del mercado
Conferencia telefónica:
La conferencia telefónica más reciente comenzó a las 8:30 a. m., hace 7 días
Haz clic para ver el webcast
Johnson & Johnson Financials
Johnson & Johnson (JNJ) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts
Johnson & Johnson posted upbeat Q3 results; analysts stayed bullish, though RBC cut its target and noted mixed product and MedTech trends.
Priya Nigam
These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results
Johnson & Johnson beat Q3 estimates and raised full-year guidance; sales rose 5.9%, EPS fell 7.5%. Analysts trimmed price targets.
Avi Kapoor
Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)
Johnson & Johnson beats Q3 2026 earnings expectations with $25.39B in sales and raises its full-year revenue and profit guidance.
Vandana Singh
QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss
Johnson & Johnson beat third-quarter profit estimates and raised its 2026 forecast. After MedTech sales missed estimates, the stock still fell about 6%, its steepest one-day drop since April 1, 2025. XLV fell 1.1%.
Piero Cingari
Earnings Scheduled For October 13, 2026
Companies Reporting Before The Bell • Unity Bancorp (NASDAQ:UNTY) is likely to report quarterly earnings at $1.55 per share on revenue of $35.60 million. • JPMorgan Chase (NYSE:JPM) is projected to report quarterly
Benzinga Insights
PRO
Johnson & Johnson Raises FY2026 Adj EPS Guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 Est; Raises FY2026 Sales Guidance from $100.800B-$101.400B to $101.000B-$101.400B vs $101.296B Est
Johnson & Johnson (NYSE:JNJ) raises FY2026 Adj EPS guidance from $10.96-$11.11 to $11.05-$11.15 vs $11.08 analyst estimate. Raises FY2026 sales outlook from $100.800 billion-$101.400 billion to $101.000
Benzinga Newsdesk
